Pretreatment patient characteristics
| Characteristics . | Total (n = 63) . | STAT3+(n = 28) . | STAT3− (n = 35) . | P . |
|---|---|---|---|---|
| Age, y | .20 | |||
| 60 or younger | 27 | 9 | 18 | |
| Older than 60 | 36 | 19 | 17 | |
| Sex (M/F) | 32/31 | 15/13 | 17/18 | .80 |
| Disease status | 1.00 | |||
| de novo | 50 | 22 | 28 | |
| Secondary | 13 | 6 | 7 | |
| WBC count (median, ×109/L) | 20.25 | 10.31 | 29.86 | .09 |
| FAB | NA | |||
| M0 | 5 | 3 | 2 | |
| M1 | 15 | 6 | 9 | |
| M2 | 25 | 14 | 11 | |
| M3 | 3 | 0 | 3 | |
| M4 | 6 | 3 | 3 | |
| M5 | 6 | 1 | 5 | |
| M6 | 3 | 1 | 2 | |
| Cytogenetics | .73 | |||
| Favorable | 7 | 1 | 6 | |
| Intermediate | 30 | 18 | 12 | |
| Unfavorable* | 26 | 12 | 14 | |
| STAT subtype | .29 | |||
| α | 23 | 9 | 14 | |
| β | 33 | 18 | 15 |
| Characteristics . | Total (n = 63) . | STAT3+(n = 28) . | STAT3− (n = 35) . | P . |
|---|---|---|---|---|
| Age, y | .20 | |||
| 60 or younger | 27 | 9 | 18 | |
| Older than 60 | 36 | 19 | 17 | |
| Sex (M/F) | 32/31 | 15/13 | 17/18 | .80 |
| Disease status | 1.00 | |||
| de novo | 50 | 22 | 28 | |
| Secondary | 13 | 6 | 7 | |
| WBC count (median, ×109/L) | 20.25 | 10.31 | 29.86 | .09 |
| FAB | NA | |||
| M0 | 5 | 3 | 2 | |
| M1 | 15 | 6 | 9 | |
| M2 | 25 | 14 | 11 | |
| M3 | 3 | 0 | 3 | |
| M4 | 6 | 3 | 3 | |
| M5 | 6 | 1 | 5 | |
| M6 | 3 | 1 | 2 | |
| Cytogenetics | .73 | |||
| Favorable | 7 | 1 | 6 | |
| Intermediate | 30 | 18 | 12 | |
| Unfavorable* | 26 | 12 | 14 | |
| STAT subtype | .29 | |||
| α | 23 | 9 | 14 | |
| β | 33 | 18 | 15 |
Twelve patients had one aberration each—r(7), t(6;11), t(5;8), t(9;22), add(1), +8, +mar, +13, add(20), der(13;14), +2mar, or del(X)q23—and 14 had 2 or more cytogenetic aberrations.
FAB indicates French-American-British; NA, not analyzed.